Waldenströmova makroglobulinemie

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Waldenström macroglobulinemia
Authors

BAĎUROVÁ Klára GREGOROVÁ Jana VLACHOVÁ Monika KREJČÍ Marta ŠEVČÍKOVÁ Sabina

Year of publication 2021
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.linkos.cz/casopis-klinicka-onkologie/2021-12-15-6-1/waldenstr-mova-makroglobulinemie/
Doi http://dx.doi.org/10.48095/ccko2021428
Keywords Waldenström macroglobulinemia; incidence; mutation; mikroRNA; prognosis
Description Waldenström macroglobulinemia (WM) is a hematological malignancy; it is a monoclonal gammopathy, a disease characterized by presence of a monoclonal immunoglobulin in serum and/or urine. The median age at dia­gnosis is 71 years. WM is not an aggres­sive disease and patients with this dia­gnosis can live for several years. Infiltration of the bone marrow with lymphoplasmacytoid cells causes anemia, leading to various problems, mainly fatigue. Hepatomegaly, splenomegaly and lymphadenopathy can also occur. Hyperviscosity syndrome can appear and is caused by excessive production of immunoglobulin M. A mutation in MYD88 gene is detected in almost every WM patient, and in almost one third of them, a mutation in CXCR4 gene is detected. The detection of MYD88 mutation is important for a correct therapeutic strategy, since a Bruton’s tyrosine kinase inhibitor, ibrutinib, is most effective in patients with mutated MYD88 and wt CXCR4. The therapy is started when first symptoms occur. Purpose: The aim of this study is to summarize current knowledge about this disease, its dia­g­nostics, molecular basis and treatment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.